论文部分内容阅读
目的探讨血清基质金属蛋白酶-9(MMP-9)在子宫内膜腺癌中的表达与意义。方法选取我院妇产科2011年11月-2012年12月经常规病理学诊断为子宫内膜腺癌肿瘤组织30例,因卵巢及输卵管良性病变行子宫全切术的正常子宫内膜组织25例为对照组。采用逆转录-聚合酶链反应(RT-PCR)方法检测MMP-9在子宫内膜腺癌中表达情况。结果子宫内膜腺癌组与对照组阳性表达率逐渐升高,有统计学差异;子宫内膜腺癌临床分期组间差异有统计学意义;子宫内膜腺癌病理分级组间有统计学差异。结论 MMP-9蛋白在子宫内膜腺癌与临床分期与病理分级密切相关。
Objective To investigate the expression and significance of serum matrix metalloproteinase-9 (MMP-9) in endometrial adenocarcinoma. Methods Obstetrics and Gynecology of our hospital from November 2011 to December 2012 routine pathological diagnosis of endometrial adenocarcinoma tumor tissue in 30 cases, due to ovarian and tubal benign lesions in hysterectomy normal endometrial tissue 25 cases For the control group. The expression of MMP-9 in endometrial adenocarcinoma was detected by reverse transcription-polymerase chain reaction (RT-PCR). Results The positive expression rate of endometrial adenocarcinoma group and control group increased gradually with statistical significance. There was significant difference between the clinical staging group of endometrial adenocarcinoma and the pathological grading group of endometrial adenocarcinoma . Conclusion The expression of MMP-9 in endometrial adenocarcinoma is closely related to clinical stage and pathological grade.